Sohomoy
Head And Neck Cancer Drugs Therapeutics Market: PD-1/PD-L1 Immunotherapies, Targeted Combinations, and Precision Oncology Driving Growth
Rising global incidence of head and neck malignancies—including HPV-positive oropharyngeal and tobacco- or alcohol-associated tumors—expanding biomarker screening, and ongoing clinical breakthroughs in checkpoint inhibitors and targeted biologics are driving momentum across the Head And Neck Cancer Drugs Therapeutics Market, with industry benchmarks spanning roughly USD 2.46 billion...
14 Views